Table 4.

Change in mean PRO measures from baseline to week 24 and follow-up visits^a

	Time point from baseline of the ATLAS study
PRO measure	Week 24	Week 36	Week 52	Week 76	Week 104	Week 128	Week 156
BASDAI
n	288	278	274	270	262	242	236
Mean ± SD change	-3.1 ± 2.42	-3.4 ± 2.41	-3.5 ± 2.55	-3.8 ± 2.33	-3.9 ± 2.44	-3.9 ± 2.39	-3.9 ± 3.39
BASFI
n	288	b	274	270	261	242	236
Mean ± SD change	-2.2 ± 1.91	b	-2.6 ± 2.04	-2.8 ± 2.10	-2.9 ± 2.14	-2.9 ± 2.17	-3.0 ± 2.10
SF-36 PCS
n	284	b	265	263	255	229	227
Mean ± SD change	8.2 ± 9.01	b	10.19 ± 9.50	10.8 ± 9.88	11.0 ± 9.88	11.3 ± 9.68	11.6 ± 9.65
SF-36 MCS
n	284	b	265	263	255	229	227
Mean ± SD change	4.8 ± 10.27	b	5.6 ± 10.35	5.1 ± 11.06	5.7 ± 10.96	4.1 ± 10.84	5.6 ± 11.59
SF-36 Physical Function
n	287	b	273	268	261	241	235
Mean ± SD change	15.6 ± 20.99	b	19.5 ± 21.38	21.8 ± 21.79	21.9 ± 22.26	22.2 ± 22.34	23.3 ± 21.94
SF-36 Role–Physical
n	288	b	272	270	263	237	232
Mean ± SD change	30.3 ± 40.48	b	37.2 ± 40.81	35.2 ± 40.72	39.1 ± 41.75	36.1 ± 42.39	37.8 ± 43.90
SF-36 Bodily Pain
n	288	b	274	270	263	237	233
Mean ± SD change	24.0 ± 21.78	b	29.0 ± 22.96	29.7 ± 23.24	29.9 ± 23.74	31.8 ± 24.42	31.7 ± 24.33
SF-36 General Health
n	287	b	270	266	260	237	234
Mean ± SD change	8.7 ± 17.37	b	11.3 ± 18.68	12.7 ± 19.25	12.5 ± 19.92	12.0 ± 18.84	12.7 ± 18.71
SF-36 Vitality
n	288	b	274	268	263	242	236
Mean ± SD change	16.3 ± 19.82	b	19.5 ± 19.96	20.1 ± 19.65	20.4 ± 20.05	18.4 ± 19.85	20.1 ± 19.70
SF-36 Social Function
n	288	b	274	270	263	242	236
Mean ± SD change	16.1 ± 23.88	b	19.7 ± 24.50	18.5 ± 23.73	20.6 ± 25.36	17.9 ± 26.01	22.3 ± 25.16
SF-36 Role–Emotional
n	286	b	271	268	260	235	230
Mean ± SD change	17.2 ± 41.24	b	21.0 ± 44.40	19.5 ± 46.74	21.5 ± 46.01	16.9 ± 44.80	20.0 ± 46.06
SF-36 Mental Health
n	288	b	274	268	263	242	236
Mean ± SD change	8.8 ± 16.52	b	10.1 ± 17.15	10.2 ± 17.50	10.6 ± 16.63	8.7 ± 16.96	10.5 ± 18.32
ASQOL
n	288	b	274	270	263	242	236
Mean ± SD change	-4.1 ± 4.23	b	-4.8 ± 4.41	-5.0 ± 4.32	-5.4 ± 4.28	-5.3 ± 4.35	-5.4 ± 4.36

^aAll values P < 0.001 compared with baseline based on paired Student t-test.

^bMeasure not assessed at this time point.

ASQOL = AS Quality of Life Questionnaire; ATLAS = Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS; BASDAI = Bath AS Disease Activity Index; BASFI = Bath AS Functional Index; MCS = Mental Component Summary; PCS = Physical Component Summary; PRO = patient-reported outcome; SD = standard deviation; SF-36 = Short Form-36 Health Survey.